The EVOLVE clinical trial (NCT02681237) exploratory study of anti-angiogenic drugs combined with PARPi in patients with PARPi-resistant ovarian cancer showed the following findings: BRCA1/2 or RAD51B reversion (19%) at the time of PARPi progression; ABCB1 upregulation (15%); and down-regulation of SLFN11 (7%) (Lheureux et al., 2020). Here, BRCA1 is linked to ovarian carcinoma.